Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations
Executive Summary
Roche and Genentech's plans to establish Avastin (bevacizumab) as the "backbone" standard of care in oncology include a focus on combination use
You may also be interested in...
Merck Expands Immuno-Oncology Efforts, Calls MK-3475 A Pipeline In Itself
Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer